Utilization of fine-needle aspiration biopsy (FNAB) cytology for the diagnosis of diseases of the breast has been met with both excitement and uncertainty during the last couple of decades. Presently, FNAB for the diagnosis of primary and metastatic breast lesions is on the rise again. This is probably due to its fast turnaround time, cost efficiency, and minimal invasiveness, characteristics of this sampling modality which are particularly crucial for patients requiring frequent repeat biopsy in the setting of metastatic lesions. In this article, we will briefly review the main modern applications of FNAB of the breast when coupled with contemporary ancillary techniques. Such contemporary ancillary techniques range from classic immunocytochemistry (ICC) to the most modern molecular techniques, particularly next-generation sequencing. Coupled with contemporary ICC and molecular methods, FNAB of the breast can be used for several applications. The applications reviewed in this article include the primary diagnosis of a breast lesion, the identification of the breast as a primary source of a metastatic lesion, the evaluation of breast prognostic/predictive markers, and the tracking of tumor evolution. In our opinion, FNAB of the breast is an ideal sampling method, sharing many of the advantages of truly liquid and of tissue biopsies. Ultimately, we aim at demystifying the complexity of many of the challenges traditionally associated with the application of ancillary techniques to FNAB of the breast and provide insights into some of the most cutting-edge and clinically useful application scenarios.

1.
Filho
AL
,
Gonçalves
AE
,
Martinho
O
,
Schmitt
FC
,
Reis
RM
.
Liquid-based cytology in DNA-based molecular research: viability and potential application
.
Anal Quant Cytol Histol
.
2009
Dec
;
31
(
6
):
395
400
.
[PubMed]
0884-6812
2.
Marinšek
ZP
,
Nolde
N
,
Kardum-Skelin
I
,
Nizzoli
R
,
Onal
B
,
Rezanko
T
, et al
Multinational study of oestrogen and progesterone receptor immunocytochemistry on breast carcinoma fine needle aspirates
.
Cytopathology
.
2013
Feb
;
24
(
1
):
7
20
.
[PubMed]
0956-5507
3.
Reis-Filho
JS
,
Milanezi
F
,
Amendoeira
I
,
Albergaria
A
,
Schmitt
FC
.
p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast
.
J Clin Pathol
.
2002
Dec
;
55
(
12
):
936
9
.
[PubMed]
0021-9746
4.
Hoshikawa
S
,
Sano
T
,
Hirato
J
,
Oyama
T
,
Fukuda
T
.
Immunocytochemical analysis of p63 and 34βE12 in fine needle aspiration cytology specimens for breast lesions: a potentially useful discriminatory marker between intraductal papilloma and ductal carcinoma in situ
.
Cytopathology
.
2016
Apr
;
27
(
2
):
108
14
.
[PubMed]
0956-5507
5.
Reis-Filho
JS
,
Milanezi
F
,
Amendoeira
I
,
Albergaria
A
,
Schmitt
FC
.
Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples
.
Cancer
.
2003
Jun
;
99
(
3
):
172
9
.
[PubMed]
0008-543X
6.
Skoog
L
,
Tani
E
.
Immunocytochemistry: an indispensable technique in routine cytology
.
Cytopathology
.
2011
Aug
;
22
(
4
):
215
29
.
[PubMed]
0956-5507
7.
Elmore
JG
,
Longton
GM
,
Carney
PA
,
Geller
BM
,
Onega
T
,
Tosteson
AN
, et al
Diagnostic concordance among pathologists interpreting breast biopsy specimens
.
JAMA
.
2015
Mar
;
313
(
11
):
1122
32
.
[PubMed]
0098-7484
8.
Rakha
EA
,
Miligy
IM
,
Gorringe
KL
,
Toss
MS
,
Green
AR
,
Fox
SB
, et al
Invasion in breast lesions: the role of the epithelial-stroma barrier
.
Histopathology
.
2018
Jun
;
72
(
7
):
1075
83
.
[PubMed]
0309-0167
9.
Aiad
HA
,
Abd El-Halim Kandil
M
,
Abd El-Wahed
MM
,
Abdou
AG
,
Hemida
AS
.
Diagnostic role of p63 immunostaining in fine needle aspiration cytology of different breast lesions
.
Acta Cytol
.
2011
;
55
(
2
):
149
57
.
[PubMed]
0001-5547
10.
Bu
D
,
Lewis
CM
,
Sarode
V
,
Chen
M
,
Ma
X
,
Lazorwitz
AM
, et al
Identification of breast cancer DNA methylation markers optimized for fine-needle aspiration samples
.
Cancer Epidemiol Biomarkers Prev
.
2013
Dec
;
22
(
12
):
2212
21
.
[PubMed]
1055-9965
11.
Euhus
DM
,
Bu
D
,
Milchgrub
S
,
Xie
XJ
,
Bian
A
,
Leitch
AM
, et al
DNA methylation in benign breast epithelium in relation to age and breast cancer risk
.
Cancer Epidemiol Biomarkers Prev
.
2008
May
;
17
(
5
):
1051
9
.
[PubMed]
1055-9965
12.
Downs
BM
,
Mercado-Rodriguez
C
,
Cimino-Mathews
A
,
Chen
C
,
Yuan
JP
,
van den Berg
E
, et al
DNA Methylation Markers for Breast Cancer Detection in the Developing World: Marker Training, Assay Validation
.
Automation and Pilot Testing.
submitted.
13.
Mucha Dufloth
R
,
Xavier-Júnior
JC
,
Moraes Neto
FA
,
Janoti dos Santos
K
,
Schmitt
F
.
Fine needle aspiration cytology of lobular breast carcinoma and its variants
.
Acta Cytol
.
2015
;
59
(
1
):
37
42
.
[PubMed]
0001-5547
14.
Tse
,
Gary
,
Puay Hoon
Tan
, and Schmitt, F.
2013
. “Special Ancillary Techniques: Immunohistochemistry.” In Fine Needle Aspiration Cytology of the Breast: Atlas of Cyto-Histologic Correlates, 159–68. Berlin, Heidelberg: Springer Berlin Heidelberg.
15.
Dabbs
DJ
,
Schnitt
SJ
,
Geyer
FC
,
Weigelt
B
,
Baehner
FL
,
Decker
T
, et al
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry
.
Am J Surg Pathol
.
2013
Jul
;
37
(
7
):
e1
11
.
[PubMed]
0147-5185
16.
Shinagawa
T
,
Tadokoro
M
,
Kitamura
H
,
Mizuguchi
K
,
Kushima
M
.
Secretory carcinoma of the breast. Correlation of aspiration cytology and histology
.
Acta Cytol
.
1994
Nov-Dec
;
38
(
6
):
909
14
.
[PubMed]
0001-5547
17.
Tognon
C
,
Knezevich
SR
,
Huntsman
D
,
Roskelley
CD
,
Melnyk
N
,
Mathers
JA
, et al
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
.
Cancer Cell
.
2002
Nov
;
2
(
5
):
367
76
.
[PubMed]
1535-6108
18.
Persson
M
,
Andrén
Y
,
Mark
J
,
Horlings
HM
,
Persson
F
,
Stenman
G
.
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck
.
Proc Natl Acad Sci USA
.
2009
Nov
;
106
(
44
):
18740
4
.
[PubMed]
0027-8424
19.
Reis-Filho
JS
,
Milanezi
F
,
Paredes
J
,
Silva
P
,
Pereira
EM
,
Maeda
SA
, et al
Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast
.
Appl Immunohistochem Mol Morphol
.
2003
Mar
;
11
(
1
):
1
8
.
[PubMed]
1541-2016
20.
Reis-Filho
JS
,
Schmitt
FC
.
p63 expression in sarcomatoid/metaplastic carcinomas of the breast
.
Histopathology
.
2003
Jan
;
42
(
1
):
94
5
.
[PubMed]
0309-0167
21.
Tan
BY
,
Acs
G
,
Apple
SK
,
Badve
S
,
Bleiweiss
IJ
,
Brogi
E
, et al
Phyllodes tumours of the breast: a consensus review
.
Histopathology
.
2016
Jan
;
68
(
1
):
5
21
.
[PubMed]
0309-0167
22.
Tsang
JY
,
Mendoza
P
,
Lam
CC
,
Yu
AM
,
Putti
TC
,
Karim
RZ
, et al
Involvement of α- and β-catenins and E-cadherin in the development of mammary phyllodes tumours
.
Histopathology
.
2012
Oct
;
61
(
4
):
667
74
.
[PubMed]
0309-0167
23.
Hayes
MJ
,
Thomas
D
,
Emmons
A
,
Giordano
TJ
,
Kleer
CG
.
Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast
.
Clin Cancer Res
.
2008
Jul
;
14
(
13
):
4038
44
.
[PubMed]
1078-0432
24.
Cimino-Mathews
A
,
Sharma
R
,
Illei
PB
,
Vang
R
,
Argani
P
.
A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies
.
Am J Surg Pathol
.
2014
Dec
;
38
(
12
):
1689
96
.
[PubMed]
0147-5185
25.
Noronha
Y
,
Raza
A
,
Hutchins
B
,
Chase
D
,
Garberoglio
C
,
Chu
P
, et al
CD34, CD117, and Ki-67 expression in phyllodes tumor of the breast: an immunohistochemical study of 33 cases
.
Int J Surg Pathol
.
2011
Apr
;
19
(
2
):
152
8
.
[PubMed]
1066-8969
26.
DeLair
DF
,
Corben
AD
,
Catalano
JP
,
Vallejo
CE
,
Brogi
E
,
Tan
LK
.
Non-mammary metastases to the breast and axilla: a study of 85 cases
.
Mod Pathol
.
2013
Mar
;
26
(
3
):
343
9
.
[PubMed]
0893-3952
27.
Ravdel
L
,
Robinson
WA
,
Lewis
K
,
Gonzalez
R
.
Metastatic melanoma in the breast: a report of 27 cases
.
J Surg Oncol
.
2006
Aug
;
94
(
2
):
101
4
.
[PubMed]
0022-4790
28.
Gillett
CE
,
Bobrow
LG
,
Millis
RR
.
S100 protein in human mammary tissue—immunoreactivity in breast carcinoma, including Paget’s disease of the nipple, and value as a marker of myoepithelial cells
.
J Pathol
.
1990
Jan
;
160
(
1
):
19
24
.
[PubMed]
0022-3417
29.
Talwalkar
SS
,
Miranda
RN
,
Valbuena
JR
,
Routbort
MJ
,
Martin
AW
,
Medeiros
LJ
.
Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms
.
Am J Surg Pathol
.
2008
Sep
;
32
(
9
):
1299
309
.
[PubMed]
0147-5185
30.
Schmitt
F
,
Davidson
B
. Breast carcinoma.
Serous Effusions: etiology, diagnosis, prognosis and therapy
.
London
:
Springer Verlag
;
2012
. pp.
69
77
.
31.
Yan
Z
,
Gidley
J
,
Horton
D
,
Roberson
J
,
Eltoum
IE
,
Chhieng
DC
.
Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens
.
Diagn Cytopathol
.
2009
Jul
;
37
(
7
):
475
8
.
[PubMed]
8755-1039
32.
Chia
SY
,
Thike
AA
,
Cheok
PY
,
Tan
PH
,
Tan
P
.
Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors
.
Breast
.
2010
Oct
;
19
(
5
):
355
9
.
[PubMed]
0960-9776
33.
Kawaguchi
KR
,
Lu
FI
,
Kaplan
R
,
Liu
YF
,
Chadwick
P
,
Chen
Z
, et al
In search of the ideal immunopanel to distinguish metastatic mammary carcinoma from primary lung carcinoma: a tissue microarray study of 207 cases
.
Appl Immunohistochem Mol Morphol
.
2014
Apr
;
22
(
4
):
266
74
.
[PubMed]
1541-2016
34.
Cimino-Mathews
A
,
Subhawong
AP
,
Illei
PB
,
Sharma
R
,
Halushka
MK
,
Vang
R
, et al;
Cimino-Mathews
.
Ashley, Subhawong A, Illei P, Sharma R, Halushka M, Vang R, Fetting J, Park B, Argani P. GATA3 Expression in Breast Carcinoma: Utility in Triple-Negative, Sarcomatoid, and Metastatic Carcinomas
.
Hum Pathol
.
2013
;
44
(
7
):
1341
9
. 0046-8177
35.
Lew
M
,
Pang
JC
,
Jing
X
,
Fields
KL
,
Roh
MH
.
Young investigator challenge: the utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions
.
[Cancer Cytopathol]
.
Cancer Cytopathol
.
2015
Oct
;
123
(
10
):
576
81
.
[PubMed]
1934-662X
36.
El Hag
MI
,
Ha
J
,
Farag
R
,
El Hag
AM
,
Michael
CW
.
Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions: A Cell-Block Microarray Study
.
Diagn Cytopathol
.
2016
Sep
;
44
(
9
):
731
6
.
[PubMed]
8755-1039
37.
Espinosa
I
,
Gallardo
A
,
D’Angelo
E
,
Mozos
A
,
Lerma
E
,
Prat
J
.
Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases
.
Int J Gynecol Pathol
.
2015
May
;
34
(
3
):
257
65
.
[PubMed]
0277-1691
38.
Cardoso
F
,
Harbeck
N
,
Fallowfield
L
,
Kyriakides
S
,
Senkus
E
;
ESMO Guidelines Working Group
.
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
.
Ann Oncol
.
2012
Oct
;
23
Suppl 7
:
vii11
9
.
[PubMed]
0923-7534
39.
Amir
E
,
Miller
N
,
Geddie
W
,
Freedman
O
,
Kassam
F
,
Simmons
C
, et al
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer
.
J Clin Oncol
.
2012
Feb
;
30
(
6
):
587
92
.
[PubMed]
0732-183X
40.
Simmons
C
,
Miller
N
,
Geddie
W
,
Gianfelice
D
,
Oldfield
M
,
Dranitsaris
G
, et al
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
Ann Oncol
.
2009
Sep
;
20
(
9
):
1499
504
.
[PubMed]
0923-7534
41.
Wilking
U
,
Karlsson
E
,
Skoog
L
,
Hatschek
T
,
Lidbrink
E
,
Elmberger
G
, et al
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
.
Breast Cancer Res Treat
.
2011
Jan
;
125
(
2
):
553
61
.
[PubMed]
0167-6806
42.
Beca
F
,
Schmitt
F
.
Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites
.
Cancer Cytopathol
.
2014
Jul
;
122
(
7
):
504
11
.
[PubMed]
1934-662X
43.
Dong
J
,
Ly
A
,
Arpin
R
,
Ahmed
Q
,
Brachtel
E
.
Breast fine needle aspiration continues to be relevant in a large academic medical center: experience from Massachusetts General Hospital
.
Breast Cancer Res Treat
.
2016
Jul
;
158
(
2
):
297
305
.
[PubMed]
0167-6806
44.
Hammond
ME
,
Hayes
DF
,
Dowsett
M
,
Allred
DC
,
Hagerty
KL
,
Badve
S
, et al
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
.
Arch Pathol Lab Med
.
2010
Jun
;
134
(
6
):
907
22
.
[PubMed]
1543-2165
45.
Wolff
AC
,
Hammond
ME
,
Allison
KH
,
Harvey
BE
,
Mangu
PB
,
Bartlett
JM
, et al
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
.
Arch Pathol Lab Med
.
2018
Nov
;
142
(
11
):
1364
82
.
[PubMed]
0003-9985
46.
Schmitt
F
,
Vielh
P
.
Fine-needle aspiration cytology samples: a good source of material for evaluating biomarkers in breast cancer
.
Histopathology
.
2015
Jan
;
66
(
2
):
314
5
.
[PubMed]
0309-0167
47.
Ahn
S
,
Lee
J
,
Cho
MS
,
Park
S
,
Sung
SH
.
Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens
.
Arch Pathol Lab Med
.
2018
Mar
;
142
(
3
):
364
8
.
[PubMed]
0003-9985
48.
Morimoto
M
,
Bando
Y
,
Nakagawa
M
,
Takechi
H
,
Yoshida
T
,
Honda
J
, et al
Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable
.
Breast Cancer
.
2016
Jul
;
23
(
4
):
577
82
.
[PubMed]
1340-6868
49.
Robertson
S
,
Stålhammar
G
,
Darai-Ramqvist
E
,
Rantalainen
M
,
Tobin
NP
,
Bergh
J
, et al
Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer
.
J Clin Pathol
.
2018
Sep
;
71
(
9
):
787
94
.
[PubMed]
0021-9746
50.
Kos
Z
,
Dabbs
DJ
.
Biomarker assessment and molecular testing for prognostication in breast cancer
.
Histopathology
.
2016
Jan
;
68
(
1
):
70
85
.
[PubMed]
0309-0167
51.
Polley
MY
,
Leung
SC
,
Gao
D
,
Mastropasqua
MG
,
Zabaglo
LA
,
Bartlett
JM
, et al
An international study to increase concordance in Ki67 scoring
.
Mod Pathol
.
2015
Jun
;
28
(
6
):
778
86
.
[PubMed]
0893-3952
52.
Wasserman
BE
,
Carvajal-Hausdorf
DE
,
Ho
K
,
Wong
W
,
Wu
N
,
Chu
VC
, et al
High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence
.
Lab Invest
.
2017
Dec
;
97
(
12
):
1521
6
.
[PubMed]
0023-6837
53.
Wong
E
,
Wu
N
,
Acca
B
,
Dias
H
.
GeneXpert® breast cancer STRAT4 assay demonstrates high concordance of ESR1, PgR, HER2, and Ki67 with central IHC and FISH testing in FFPE breast tumor tissues
.
Breast
.
2018
;
32
:
S49
. 0960-9776
54.
Cardoso
F
,
Senkus
E
,
Costa
A
,
Papadopoulos
E
,
Aapro
M
,
André
F
, et al
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
.
Ann Oncol
.
2018
Aug
;
29
(
8
):
1634
57
.
[PubMed]
0923-7534
55.
Beca
F
,
Polyak
K
. Intratumor heterogeneity in breast cancer. In:
Stearns
V
, editor
.
Advances in Experimental Medicine and Biology
.
Cham
:
Springer International Publishing
;
2016
. pp.
169
89
.
56.
Holst
F
,
Moelans
CB
,
Filipits
M
,
Singer
CF
,
Simon
R
,
van Diest
PJ
.
On the evidence for ESR1 amplification in breast cancer
.
Nat Rev Cancer
.
2012
Jan
;
12
(
2
):
149
.
[PubMed]
1474-175X
57.
Holst
F
,
Stahl
PR
,
Ruiz
C
,
Hellwinkel
O
,
Jehan
Z
,
Wendland
M
, et al
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
.
Nat Genet
.
2007
May
;
39
(
5
):
655
60
.
[PubMed]
1061-4036
58.
Tomita
S
,
Zhang
Z
,
Nakano
M
,
Ibusuki
M
,
Kawazoe
T
,
Yamamoto
Y
, et al
Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients
.
Cancer Sci
.
2009
Jun
;
100
(
6
):
1012
7
.
[PubMed]
1347-9032
59.
Lin
CH
,
Liu
JM
,
Lu
YS
,
Lan
C
,
Lee
WC
,
Kuo
KT
, et al
Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation
.
J Clin Pathol
.
2013
Feb
;
66
(
2
):
140
5
.
[PubMed]
0021-9746
60.
Jeselsohn
R
,
Buchwalter
G
,
De Angelis
C
,
Brown
M
,
Schiff
R
.
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
.
Nat Rev Clin Oncol
.
2015
Oct
;
12
(
10
):
573
83
.
[PubMed]
1759-4774
61.
Cancer Genome Atlas Network
.
Comprehensive molecular portraits of human breast tumours
.
Nature
.
2012
Oct
;
490
(
7418
):
61
70
.
[PubMed]
0028-0836
62.
Toy
W
,
Shen
Y
,
Won
H
,
Green
B
,
Sakr
RA
,
Will
M
, et al
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
.
Nat Genet
.
2013
Dec
;
45
(
12
):
1439
45
.
[PubMed]
1061-4036
63.
Robinson
DR
,
Wu
YM
,
Vats
P
,
Su
F
,
Lonigro
RJ
,
Cao
X
, et al
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
.
Nat Genet
.
2013
Dec
;
45
(
12
):
1446
51
.
[PubMed]
1061-4036
64.
Kuderer
NM
,
Burton
KA
,
Blau
S
,
Rose
AL
,
Parker
S
,
Lyman
GH
, et al
Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology
.
JAMA Oncol
.
2017
Jul
;
3
(
7
):
996
8
.
[PubMed]
2374-2437
65.
Razavi
P
,
Chang
MT
,
Xu
G
,
Bandlamudi
C
,
Ross
DS
,
Vasan
N
, et al
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
.
Cancer Cell
.
2018
Sep
;
34
(
3
):
427
438.e6
.
[PubMed]
1535-6108
66.
Beca
F
,
Beck
AH
.
Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials
.
PLoS Med
.
2016
Dec
;
13
(
12
):
e1002177
.
[PubMed]
1549-1277
67.
Martins
D
,
Beca
F
,
Schmitt
F
.
Metastatic breast cancer: mechanisms and opportunities for cytology
.
Cytopathology
.
2014
Aug
;
25
(
4
):
225
30
.
[PubMed]
0956-5507
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.